Low-dose iodine-131 metaiodobenzylguanidine therapy for patients with malignant pheochromocytoma and paraganglioma: Single center experience

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 33, Issue 1, 2010, Pages 79-82

  Shilkrut, Mark ^a,b   Bar Deroma, Raquel ^a,b   Bar Sela, Gil ^a,b   Berniger, Alison ^a   Kuten, Abraham ^a,b  

^a Division of Oncology   (Israel)

^b TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

131 I MIBG; Iodine 131 metaiodobenzylguanidine; Malignant; Paraganglioma; Pheochromocytoma; Radionuclide therapy

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 123; METOCLOPRAMIDE;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER SURGERY; CANCER SURVIVAL; CLINICAL ARTICLE; EXTERNAL BEAM RADIOTHERAPY; FEMALE; HORMONE ACTION; HUMAN; HYPOTHYROIDISM; MALE; NAUSEA AND VOMITING; PARAGANGLIOMA; PHEOCHROMOCYTOMA; PROGRESSION FREE SURVIVAL; RADIOISOTOPE THERAPY; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT RESPONSE;

3-IODOBENZYLGUANIDINE; ADRENAL GLAND NEOPLASMS; ADULT; AGED; ANTINEOPLASTIC AGENTS; DOSE-RESPONSE RELATIONSHIP, RADIATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; NEOPLASM STAGING; PARAGANGLIOMA; PHEOCHROMOCYTOMA; PROGNOSIS; SURVIVAL RATE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 76749164800     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/COC.0b013e31819e2c28     Document Type: Article

References (20)

1. Chrisoulidou A, Kaltsas G, Ilias I, et al. The diagnosis and management of malignant phaeochromocytoma and paraganglioma. Endocr Relat Cancer. 2007;14:569-585.
2. Scholtz T, Eisenhofer G, Pacak K, et al. Clinical review: current treatment of malignant pheochromocytoma. J Clin Endocrinol Metab. 2007;92:1217-1225.
3. Hartley A, Spooner D, Brunt AM. Management of malignant phaechromocytoma: a retrospective review of the use of MIBG and chemotherapy in the West Midlands. Clin Oncol. 2001;13:361-366.
4. Nakabeppu Y, Nakajo M. Radionuclide therapy of malignant pheochromocytoma with 131I-MIBG. Ann Nucl Med. 1994;8:259-268.
5. Shapiro B, Gross MD, Shulkin B. Radioisotope diagnosis and therapy of malignant pheochromocytoma. Trends Endocrinol Metab. 2001;12:469-475.
6. Loh KC, Fitzgerald PA, Matthay KK, et al. The treatment of malignant pheochromocytoma with iodine-131 metaiodobenzylguanidine (131I-MIBG): a comprehensive review of 116 reported patients. J Endocrinol Invest. 1997;20:648-658.
7. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst. 2000;92:205-216. (Pubitemid 30099779)
8. Eisenhofer G, Bornstein SR, Brouwers FM, et al. Malignant pheochromocytoma: current status and initiatives for future progress. Endocr Relat Cancer. 2004;11:423-436.
9. Averbuch SD, Steakley CS, Young RC, et al. Malignant pheochromocytoma: effective treatment with a combination of cyclophosphamide, vincristine and dacarbazine. Ann Intern Med. 1988;109:267-273.
10. Wu LT, Dicpinigaitis P, Bruckner H, et al. Hypertensive crises induced by treatment of malignant phaeochromocytoma with a combination of cyclophosphamide, vincristine, and dacarbazine. Med Ped Oncol. 1994;22:389-392.
11. Sisson JC, Shapiro B, Beierwaltes WH, et al. Radiopharmaceutical treatment of malignant pheochromocytoma. J Nucl Med. 1984;25:197-206.
12. Gedik GK, Hoefnagel CA, Bais E, et al. 131I-MIBG therapy in metastatic phaeochromocytoma and paraganglioma. Eur J Nucl Med Mol Imaging. 2008;35:725-733.
13. Castellani MR, Chiti A, Seregni E, et al. Role of 131I- metaiodobenzylguanidine (MIBG) in the treatment of neuroendocrine tumours. Experience of the National Cancer Institute of Milan. Q J Nucl Med. 2000;44:77-87.
14. Safford SD, Coleman RE, Gockerman JP, et al. Iodine-131 metaiodobenzylguanidine is an effective treatment for malignant pheochromocytoma and paraganglioma. Surgery. 2003;134:956-963.
15. Brans B, Monsieurs M, Laureys G, et al. Thyroidal uptake and radiation dose after repetitive I-131-MIBG treatments: influence of potassium iodide for thyroid blocking. Med Pediatr Oncol. 2002;38:41-46. (Pubitemid 34037711)
16. Rose B, Matthay KK, Price D, et al. High-dose 131-I- metaiodobenzylguanidine therapy for 12 patients with malignant pheochromocytoma. Cancer. 2003;98:239-248.
17. Sisson JC, Shapiro B, Shulkin BL, et al. Treatment of malignant pheochromocytomas with 131-I metaiodobenzylguanidine and chemotherapy. Am J Clin Oncol. 1999;22:364-370.
18. Boyd M, Cunningham SH, Brown MM, et al. Noradrenaline transporter gene transfer for radiation cell kill by 131l metaiodobenzylguanidine. Gene Ther. 1999;6:1147-1452.
19. Armour A, Cunningham SH, Gaze MN, et al. The effect of cisplatin pretreatment on the accumulation of MIBG by neuroblastoma cells in vitro. Br J Cancer. 1997;75:470-476.
20. Montaldo PG, Raffaghello L, Guarnaccia F, et al. Increase of metaiodobenzylguanidine uptake and intracellular half-life during differentiation of human neuroblastoma cells. Int J Cancer. 1996;67:95-100.